The general mood among these heavyweight investors is divided, with 29% leaning bullish and 23% bearish. Among these notable options, 3 are puts, totaling $82,775, and 14 are calls, amounting to ...

I am upgrading Dyne Therapeutics stock to a 'Buy' rating due to promising late-stage DM1 and DMD drug candidates and ...